-
A phase 1, open-label, dose escalation clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARV-110 in patients with metastatic castration-resistant prostate cancer who have progressed on at least two prior systemic therapies
Available in 15 location(s)
-
A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28)WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Available in 4 location(s)
-
A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 509 in Subjects With Metastatic Castration-resistant Prostate Cancer
Available in 1 location(s)
-
A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Characterised by PTEN deficiency (CAPItello-281)
Available in 20 location(s)
-
A Phase I, Open-label, Multi-center, Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-Tumor Activity of AC176 in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) Who Have Progressed on at Least Two Prior Systemic Therapies
Available in 19 location(s)
-
A Phase 1b Open-Label, Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of ARV-110 in Combination with Abiraterone in Patients with Metastatic Prostate Cancer
Available in 27 location(s)
-
A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC)
Available in 18 location(s)
-
CYCLONE 3 (I3Y-MC-JPEG): A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone plus Prednisone with or without Abemaciclib in Patient with High-Risk Metastatic Hormone-Sensitive Prostate Cancer
Available in 22 location(s)
-
A Phase 1 Study of JNJ-80038114, a T-Cell Redirecting Agent Targeting Prostate SpecificMembrane Antigen (PSMA), for Advanced Stage Prostate Cancer
Available in 15 location(s)
-
A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF-06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC), CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL)
Available in 16 location(s)
